SCHEMBL4370201

SCHEMBL4370201

CS(=O)(=O)Nc1cccc(CCN)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.66
NR3C1 P04150 1/20 0.52
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
KEAP1 Q14145 1/20 0.48
GHSR Q92847 1/20 0.47
POLB P06746 1/20 0.46
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
ADRA2C P18825 1/20 0.46
ADRA1A P35348 1/20 0.46
ADRA1B P35368 1/20 0.46
OPRM1 P35372 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284909 0.86 HTR6 (0.64) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL12569386 0.85 HTR6 (0.64) HTR6SMN1; SMN2TAAR1GHSRADRA1A
Hydrochloric Acid SCHEMBL2554758 0.85 HTR6 (0.62) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL6840091 0.85 NR3C1 (0.54) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL246185 0.83 ALDH1A1 (0.53) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL8867295 0.82 NR3C1 (0.51) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL10652433 0.81 NR3C1 (0.48) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL7902370 0.81 PTGS1 (0.59) NR3C1ALDH1A1SMN1; SMN2KEAP1POLB
SCHEMBL5262193 0.81 NR3C1 (0.56) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1
SCHEMBL14131241 0.81 NR3C1 (0.50) HTR6NR3C1ALDH1A1SMN1; SMN2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
CN-101619038-A Isoquinoline compound or salt thereof, medicinal composition, preparation method and application thereof SHANGHAI INST PHARM INDUSTRY 2010-01-06 CN disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
WO-2009012375-A2 SQUARATE KINASE INHIBITORS WYETH (US) 2009-01-22 WO disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 HTR6 896/4885NR3C1 1501/4885ALDH1A1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.